Eris Lifesciences Limited
ERIS · General/Diversified · NSE
₹1,465
Current Market Price
Fair Value (DCF)
₹574
Margin of Safety
-60.8%
Updated just now
YieldIQ Score
56/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
27%
ROE
10.8%
Debt/Equity
0.00
WACC
12.8%
Market Cap
₹0.20 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
12.7%
Return on capital employed
EV / EBITDA
20.5×
Enterprise multiple
Debt / EBITDA
2.2×
Leverage vs earnings
Interest Coverage
3.1×
EBIT covers interest
Current Ratio
0.89×
Short-term liquidity
Asset Turnover
0.43×
Revenue per ₹ of assets
Revenue CAGR (3Y)
22.1%
3-year revenue growth
Revenue CAGR (5Y)
20.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,465
Bear case
₹327.47
MoS -347.4%
Base case
₹574.04
MoS -155.2%
Bull case
₹748.89
MoS -95.6%
Ratio Trends
ERIS · last 8 annual periods
ROE
10.8%
ROCE
18.0%
Operating Margin
—
Debt / Equity
0.76×
PE
128.9×
EV / EBITDA
14.7×
Historical Financials
ERIS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1212 Cr | ₹1347 Cr | ₹1685 Cr | ₹2009 Cr | ₹2879 Cr | +24.2% |
| EBITDA | — | ₹511 Cr | ₹548 Cr | ₹699 Cr | ₹1036 Cr | +19.3% |
| EBIT | ₹396 Cr | ₹446 Cr | ₹431 Cr | ₹516 Cr | — | +6.8% |
| PAT | ₹355 Cr | ₹406 Cr | ₹374 Cr | ₹397 Cr | ₹352 Cr | -0.2% |
| EPS (diluted) | ₹26.14 | ₹29.88 | ₹28.07 | ₹28.79 | — | +2.4% |
| CFO | ₹375 Cr | ₹378 Cr | ₹292 Cr | ₹486 Cr | ₹1065 Cr | +29.8% |
| CapEx | — | — | — | — | ₹-155 Cr | — |
| FCF | — | — | — | — | ₹910 Cr | +0.0% |
| Total Assets | — | ₹2272 Cr | ₹3667 Cr | ₹7049 Cr | ₹7033 Cr | +32.6% |
| Total Debt | — | — | ₹186 Cr | ₹2081 Cr | ₹2478 Cr | +91.2% |
| Shareholders' Equity | — | — | ₹2196 Cr | ₹2586 Cr | ₹3272 Cr | +10.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ERIS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| NATCOPHARM NATCOPHARM | — | — | Pending | 24.8% | — |
| ASTRAZEN ASTRAZEN | — | — | Pending | 15.0% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
| GLAND GLAND | — | — | Pending | 7.6% | — |
| EMCURE EMCURE | — | — | Pending | 14.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
5 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹20.71/sh
Last payout
2025-02-13
₹7.35
Peak payout
₹7.35
Trailing yield
—
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ERIS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ERIS →
Compare
Head-to-head with peers
Compare ERIS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ERISNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.